Thomas Siler, MD
Pulmonary Disease · Saint Charles, MONPI 1881633931
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,266 of the $146,501 with a category attached, or 67.8%. 45 manufacturers reported payments, led by GSK at 39.3% of the total. Reporting peaked in 2019 at $80,785 and has fallen 96.0% since, to $3,265 in 2025. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 710 payments — averaging $206.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$58K
- Mylan Specialty L.p.$55K
- AstraZeneca$10K
- Sunovion Pharmaceuticals Inc.$9K
- Vapotherm Inc$3K
- Chiesi USA, Inc.$2K
- plus $9K from 39 others
Across 532 payments — averaging $10,021 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$926K
- Verona Pharma, Inc.$747K
- Genentech, Inc.$725K
- Sanofi US Services Inc.$722K
- Chiesi USA, Inc.$507K
- Novartis$383K
- plus $1.3M from 9 others
What the payments were for
- Consulting fees$21,38315%
- Speaking & faculty fees$99,26668%
- Travel & lodging$11,7138%
- Food & beverage$14,06510%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$54,068
- TRELEGY ELLIPTA$24,371
- ANORO$9,851
- LONHALA MAGNAIR$9,000
- NUCALA$6,953
- Precision Flow$3,421
- BREZTRI AEROSPHERE$2,900
- BREZTRI$2,850
- Inspire$700
- DUPIXENT$508
- LUMRYZ$200
- BREO$166
- XYWAV$150
- XYREM$150
- WAYRILZ$146
- Ohtuvayre$140
- ANORO ELLIPTA$109
- XOLAIR$102
How this compares
$146,501 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $69,598 |
| Breo ElliptaFluticasone/Vilanterol | 98 | $43,303 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $23,798 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 35 | $7,546 |
| Arnuity ElliptaFluticasone Furoate | 13 | $4,286 |
| Modafinil | 41 | $3,937 |
| Dextroamphetamine Sulfate | 25 | $3,303 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 118 | $3,100 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 11 | $2,661 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,425 |
| Methylphenidate Hcl | 24 | $1,118 |
| Zolpidem Tartrate | 70 | $583 |
| Ipratropium Bromide | 21 | $558 |
| Prednisone | 71 | $356 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix, Arnuity Ellipta | $57,540 | $148,532273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Charles
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Bobby ShahChesterfield$241K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.